Table 1: Symptoms of RA
Table 2: Risk Factors and Comorbidities of RA
Table 3: 1987 ACR Diagnostic Criteria for RA
Table 4: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA
Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA
Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA
Table 7: 8MM, Sources Used to Forecast Severity Segmentation of the Diagnosed Prevalent Cases of RA
Table 8: 8MM, Sources Not Used in the Epidemiological Analysis of RA
Table 9: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015–2025
Table 10: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N (Row %), 2015
Table 11: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N (Row %), 2015
Table 12: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015–2025
Table 13: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N (Row %), 2015
Table 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015
Table 15: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015–2025
Table 16: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2015
Table 17: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015
Table 18: 1987 ACR Diagnostic Criteria for RA
Table 19: 2010 ACR/EULAR Diagnostic Criteria for RA
Table 20: Treatment Guidelines for RA Used by Each Country in the 8MM
Table 21: ACR 2015 Criteria for RA Remission and Low/Moderate/High Disease Activity
Table 22: EULAR 2013 Criteria for RA Remission
Table 23: Most-Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2015
Table 24: RA Treatment Country Profile – US
Table 25: RA Treatment Country Profile – France
Table 26: RA Treatment Country Profile – Germany
Table 27: RA Treatment Country Profile – Italy
Table 28: RA Treatment Country Profile – Spain
Table 29: RA Treatment Country Profile – UK
Table 30: RA Treatment Country Profile – Japan
Table 31: RA Treatment Country Profile – Australia
Table 32: Leading Branded Treatments for RA, 2016
Table 33: Product Profile – Enbrel
Table 34: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers
Table 35: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results
Table 36: Enbrel SWOT Analysis, 2016
Table 37: Product Profile – Humira
Table 38: Humira SWOT Analysis, 2016
Table 39: Product Profile – Remicade
Table 40: Remicade SWOT Analysis, 2016
Table 41: Product Profile – Simponi
Table 42: Simponi SWOT Analysis, 2016
Table 43: Product Profile – Cimzia
Table 44: Cimzia SWOT Analysis, 2016
Table 45: Product Profile – Orencia
Table 46: Orencia SWOT Analysis, 2016
Table 47: Product Profile – Actemra
Table 48: Actemra SWOT Analysis, 2016
Table 49: Product Profile – Rituxan
Table 50: Rituxan SWOT Analysis, 2016
Table 51: Product Profile – Inflectra/Remsima
Table 52: Inflectra/Remsima SWOT Analysis, 2016
Table 53: Product Profile – Flixabi
Table 54: Flixabi SWOT Analysis, 2016
Table 55: Product Profile – Benepali
Table 56: Benepali SWOT Analysis, 2016
Table 57: Product Profile – Erelzi
Table 58: Erelzi SWOT Analysis, 2016
Table 59: Product Profile – Amjevita
Table 60: Amjevita SWOT Analysis, 2016
Table 61: Product Profile – Xeljanz
Table 62: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6
Table 63: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6
Table 64: Xeljanz SWOT Analysis, 2016
Table 65: Product Profile – Iguratimod
Table 66: Iguratimod SWOT Analysis, 2016
Table 67: Product Profile – MTX
Table 68: MTX SWOT Analysis, 2016
Table 69: Marketed and Pipeline Biosimilars for RA, 2016
Table 70: Biosimilar Legislations Across the 8MM
Table 71: Physician Uptake of Biosimilar Products for RA Across the 8MM, 2016
Table 72: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2016
Table 73: Unmet Needs and Opportunities in RA, 2016
Table 74: Comparison of Therapeutic Drug Classes in Development for RA, 2016
Table 75: Product Profile – Sarilumab
Table 76: MOBILITY Study Part, A, Results for Sarilumab at Week 12
Table 77: MOBILITY Study Part B, Results for Sarilumab at Week 52
Table 78: Safety Results of the Sarilumab Phase III SARIL-RA-ASCERTAIN Trial
Table 79: Laboratory Results of Sarilumab Phase III SARIL-RA-ASCERTAIN Trial
Table 80: Sarilumab SWOT Analysis, 2016
Table 81: Product Profile – Sirukumab
Table 82: SIRROUND-D Study Results for Sirukumab
Table 83: Sirukumab SWOT Analysis, 2016
Table 84: Product Profile – Clazakizumab
Table 85: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks
Table 86: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks
Table 87: Clazakizumab SWOT Analysis, 2016
Table 88: Product Profile – Vobarilizumab
Table 89: Phase IIb Study of Vobarilizumab: Efficacy Results for ITT Population at Week 12
Table 90: Vobarilizumab SWOT Analysis, 2016
Table 91: Product Profile – Mavrilimumab
Table 92: EARTH-EXPLORER 2 Results for Mavrilimumab at 24 Weeks
Table 93: EARTH-EXPLORER 2 Results for Mavrilimumab at 24 Weeks
Table 94: Mavrilimumab SWOT Analysis, 2016
Table 95: Product Profile – Denosumab
Table 96: Denosumab SWOT Analysis, 2016
Table 97: Product Profile – Baricitinib
Table 98: Phase III RA-BEAM Study Results for Baricitinib at Week 12
Table 99: Phase III RA-BEAM Study Results for Baricitinib at Week 24
Table 100: Phase III RA-BEACON Study Results for Baricitinib at Week 12 and Week 24
Table 101: Phase III RA-BUILD Study Results for Baricitnib at Week 12 and Week 24
Table 102: Baricitinib SWOT Analysis, 2016
Table 103: Product Profile – Peficitinib
Table 104: Peficitinib SWOT Analysis, 2016
Table 105: Product Profile – Filgotinib
Table 106: DARWIN I Study Results for Filgotinib at Week 12
Table 107: DARWIN I Study Results for Filgotinib at Week 24
Table 108: DARWIN II Study Results for Filgotinib at Week 12
Table 109: DARWIN II Study Results for Filgotinib at Week 24
Table 110: Filgotinib SWOT Analysis, 2016
Table 111: Product Profile – Upadacitinib
Table 112: Upadacitinib Phase IIb BALANCE-I Trial, ACR Responses at Week 12
Table 113: Upadacitinib Phase IIb BALANCE-II Trial, ACR Responses at Week 12
Table 114: Upadacitinib SWOT Analysis, 2016
Table 115: Product Profile – Piclidenoson
Table 116: Piclidenoson SWOT Analysis, 2016
Table 117: Drugs in Phase II of Development for RA, 2016
Table 118: Key Companies in the RA Market, 2016
Table 119: AbbVie’s RA Portfolio Assessment, 2016
Table 120: AbbVie SWOT Analysis in RA, 2015–2025
Table 121: Pfizer’s RA Portfolio Assessment, 2016
Table 122: Pfizer SWOT Analysis in RA, 2015–2025
Table 123: Amgen’s RA Portfolio Assessment, 2016
Table 124: Amgen SWOT Analysis in RA, 2015–2025
Table 125: J&J’s RA Portfolio Assessment, 2016
Table 126: J&J SWOT Analysis in RA, 2015–2025
Table 127: Eli Lilly’s RA Portfolio Assessment, 2016
Table 128: Eli Lilly SWOT Analysis in RA, 2015–2025
Table 129: BMS’ RA Portfolio Assessment, 2016
Table 130: BMS SWOT Analysis in RA, 2015–2025
Table 131: UCB’s RA Portfolio Assessment, 2016
Table 132: UCB SWOT Analysis in RA, 2015–2025
Table 133: Roche’s RA Portfolio Assessment, 2016
Table 134: Roche SWOT Analysis in RA, 2015–2025
Table 135: GSK’s RA Portfolio Assessment, 2016
Table 136: GSK SWOT Analysis in RA, 2015–2025
Table 137: Sanofi’s RA Portfolio Assessment, 2016
Table 138: Sanofi SWOT Analysis in RA, 2015–2025
Table 139: AstraZeneca/MedImmune’s RA Portfolio Assessment, 2016
Table 140: AstraZeneca/MedImmune SWOT Analysis in RA, 2015–2025
Table 141: Astellas’ RA Portfolio Assessment, 2016
Table 142: Astellas SWOT Analysis in RA, 2015–2025
Table 143: Daiichi Sankyo’s RA Portfolio Assessment, 2016
Table 144: Daiichi Sankyo SWOT Analysis in RA, 2015–2025
Table 145: Samsung Bioepis’ RA Portfolio Assessment, 2016
Table 146: Samsung Bioepis’ SWOT Analysis in RA, 2015–2025
Table 147: Sandoz’s RA Portfolio Assessment, 2016
Table 148: Sandoz’s SWOT Analysis in RA, 2015–2025
Table 149: Global RA Market – Drivers and Barriers, 2015–2025
Table 150: Key Events Impacting Sales for RA in the US, 2015–2025
Table 151: RA Market in the US – Drivers and Barriers, 2015–2025
Table 152: Key Events Impacting Sales for RA in the 5EU, 2015–2025
Table 153: RA Market in 5EU – Drivers and Barriers, 2015–2025
Table 154: Key Events Impacting Sales for RA in Japan, 2015–2025
Table 155: RA Market in Japan – Drivers and Barriers, 2013–2023
Table 156: Key Events Impacting Sales for RA in Australia, 2015–2025
Table 157: RA Market in Australia – Drivers and Barriers, 2013–2023
Table 158: 8MM, Key Launch Dates of RA Products
Table 159: 8MM, Key Patent Expiries of RA Products
Table 160: High-Prescribing Physicians (non-KOLs) Surveyed, By Country